[1] POURNARAS S, PROTONOTARIOU E, VOULGARI E, et al.Clonal spread of KPC -2 carbapenemase -producing Klebsiella pneumoniae strains in Greece[J]. Journal of Antimicrobial Chemotherapy, 2009, 64(2): 348-52. [2] European Centre for Disease Prevention and Control. Annual epidemiological report on communicable diseases in Europe[M].Stockholm: European Centre for Disease Prevention and Control,2014. [3] Centers for disease control and prevention. Facility guidance for control of carbapenem- resistant Enterobacteriaceae (CRE) 2015 update[S/OL].[2020-10-18]. https://www.cdc.gov/hai/pdfs/cre/cre-guidance-508.pdf. [4] CHEN L, MATHEMA B, CHAVDA KD, et a1. Carbapenemase producing Klebsiella pneumoniae:molecular and genetic decoding[J]. Trends Microbiol, 2014, 22(12): 686-696. [5] YANG L, ZHANG ZJ, QIN XS.Carbapenem-resistanct Klebsiella pneumoniae:Resistant mechanisms and risk factors[J]. Chinese Journal of Antibiotics(中国抗生素杂志), 2018, 43(2): 53-58. [6] TZOUVELEKIS LS, MARKOGIANNAKIS A, PSICHOGIOU M, et al.Carbapenemases in Klebsiella pneumoniae and other enterobacteriaceae: an evolving crisis of global dimensions[J]. Clinical Microbiology Reviews, 2012, 25(4):682-707. [7] SHI Y, HUANG Y, ZHANG TT, et al.Chinese guidelines for the diagnosis and treatment of hospital-acquired pneumonia and ventilator-associated pneumonia in adults (2018 Edition)[J]. Journal of Thoracic Disease, 2019, 11(6): 2581-2616. [8] PAUL M, CARMELI Y, DURANTE-MANGONI E, et al.Combination therapy for carbapenem-resistant Gram-negative bacteria[J]. Journal of Antimicrob Chemother, 2014, 69:2305-2309. [9] Chinese Society of Hematology, Chinese Medical Association, Chinese Hematology Association, Chinese Medical Doctor Association.Management of Carbapenem- resistant Enterobacteriaceae(CRE) infection in patients with hematological malignancies: Chinese consensus(2020)[J]. Chinese Journal of Hematology(中华血液学杂志), 2020, 41(11): 881-889. [10] SHIELDS RK, NGUYEN MH, CHEN L, et al. Ceftazidime-avibactamis superior to other treatment regimens against carbapenem-resistant Klebsiella pneumonia bacteremia[J]. Antimicrobial Agents and Chemotherapy, 2017, 61(8):AAC.00883-17. [11] MARIO T, MARIA TE, GIUSEPPE DRF, et al.Infections caused by KPC-producing Klebsiella pneumoniae: differences in therapy and mortality in a multicenter study[J]. J Antimicrob Chemother, 2015, 70(7): 2133-2143. [12] DAIKOS GL, MARKOGIANNAKIS A.Carbapenemase-producing Klebsiella pneumoniae: (when) might we still consider treating with carbapenems?[J]. Clin Microbiol Infect, 2011, 17(8): 1135-1141. [13] Highlights of prescribing information. Center For Drug Evaluation And Research, U.S. Food and Drug Administration[EB/OL].(2019-03)[2021-01-20].https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/206494s005,s006lbl.pdf. [14] SHIRLEY M.Ceftazidime-avibactam: a review in the treatment of serious gram-negative bacterial infections[J]. Drugs, 2018, 78(5): 675-692. [15] MERDJANH, RANGARAJU M, TARRAL A.Safety and pharmacokinetics of single and multiple ascending doses of avibactamalone and in combination with ceftazidimein healthy male volunteers: results of two randomized, placebo-controlled studies[J]. Clinical Drug Investigation, 2015, 35(5): 307-317. [16] HAWKEY PM, WARREN RE, LIVERMORE DM, et al. Treatment of infections caused by multidrug-resistant gram-negative bacteria: report of the British Society for Antimicrobial Chemotherapy/Healthcare Infection Society/British Infection Association Joint Working Party?[J]. Journal of Antimicrobial Chemotherapy, 2018, 73(suppl_3): iii2-iii78. [17] HU X, ZHANG YM, LIU X, et al.Investigation and suggestion on labeling of 75 instructions for intravenous infusion anti-infective drugs[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2019, 16(3): 168-170. [18] Microbiology/Virology Review(s). Center For Drug Evaluation And Research, U.S. Food and Drug Administration[EB/OL].(2019-09-25)[2021-01-15].https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/206494Orig1s000CllinPharmR.pdf. [19] CAPONE A, GIANNELLA M, FORTINI D, et al.High rate of colistin resistance among patients with carbapenem-resistant Klebsiella pneumoniae infection accounts for an excess of mortality[J]. Clinical Microbiology and Infection, 2013, 19(1): E23-E30. [20] ZHOU R, CHENG ZZ.Pharmacists’participation in the treatment of a patient with compiicated abdominai infection secondary to invasive fungai infection[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2020,17(2):106-110. |